Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1992 Jul;45(7):579–582. doi: 10.1136/jcp.45.7.579

Comparison of proliferation rates assessed using "multiblock" and conventional tissue blocks of lung carcinoma.

D C Brown 1, K C Gatter 1
PMCID: PMC495181  PMID: 1355493

Abstract

AIMS: To compare the proliferative rates, assessed immunohistochemically, of human lung tumours using conventional paraffin wax blocks and the multitumour tissue block (MTTB) technique. METHODS: A multiblock containing 20 lung tumours (eight adenocarcinomas, five squamous cell, five small cell and two carcinoid tumours) was constructed. Sections were also cut from the original blocks of formalin fixed, paraffin wax embedded tissue used to construct the multiblock. Sections were stained with the monoclonal antibody PC10, which recognises a proliferating cell nuclear antigen, using the three stage immunoperoxidase technique. RESULTS: The proliferation rates of the lung tumours obtained using both techniques were, overall, significantly different (p = 0.05), although most cases showed good correlation. Some tumours displayed a high degree of intratumoral variation in PC10 staining. The degree of PC10 staining was in keeping with the known proliferative state of particular histological subtypes--that is, carcinoid tumours showed little staining and small cell carcinomas showed extensive positivity. CONCLUSION: The MTTB technique is a less suitable means of assessing proliferation rate in lung carcinomas than conventional tissue blocks. It should be restricted to qualitative antibody studies or quantitative studies using tumours with little intratumoral variation.

Full text

PDF
579

Images in this article

581Image
on p.581
581Image
on p.581
581Image
on p.581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battifora H. The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest. 1986 Aug;55(2):244–248. [PubMed] [Google Scholar]
  2. Bouzubar N., Walker K. J., Griffiths K., Ellis I. O., Elston C. W., Robertson J. F., Blamey R. W., Nicholson R. I. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989 Jun;59(6):943–947. doi: 10.1038/bjc.1989.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown D. C., Cole D., Gatter K. C., Mason D. Y. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. Br J Cancer. 1988 Feb;57(2):178–181. doi: 10.1038/bjc.1988.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brown D. C., Gatter K. C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990 Dec;17(6):489–503. doi: 10.1111/j.1365-2559.1990.tb00788.x. [DOI] [PubMed] [Google Scholar]
  5. Chauvel P., Courdi A., Gioanni J., Vallicioni J., Santini J., Demard F. The labelling index: a prognostic factor in head and neck carcinoma. Radiother Oncol. 1989 Mar;14(3):231–237. doi: 10.1016/0167-8140(89)90171-0. [DOI] [PubMed] [Google Scholar]
  6. Costa A., Bonadonna G., Villa E., Valagussa P., Silvestrini R. Labeling index as a prognostic marker in non-Hodgkin's lymphomas. J Natl Cancer Inst. 1981 Jan;66(1):1–5. [PubMed] [Google Scholar]
  7. Donhuijsen K. Mitosis counts: reproducibility and significance in grading of malignancy. Hum Pathol. 1986 Nov;17(11):1122–1125. doi: 10.1016/s0046-8177(86)80417-8. [DOI] [PubMed] [Google Scholar]
  8. Düe W., Dieckmann K. P., Loy V. Immunohistological determination of proliferative activity in seminomas. J Clin Pathol. 1988 Mar;41(3):304–307. doi: 10.1136/jcp.41.3.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gatter K. C., Dunnill M. S., Gerdes J., Stein H., Mason D. Y. New approach to assessing lung tumours in man. J Clin Pathol. 1986 Jun;39(6):590–593. doi: 10.1136/jcp.39.6.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gatter K. C., Dunnill M. S., Heryet A., Mason D. Y. Human lung tumours: does intermediate filament co-expression correlate with other morphological or immunocytochemical features? Histopathology. 1987 Jul;11(7):705–714. doi: 10.1111/j.1365-2559.1987.tb02684.x. [DOI] [PubMed] [Google Scholar]
  11. Hall P. A., Levison D. A., Woods A. L., Yu C. C., Kellock D. B., Watkins J. A., Barnes D. M., Gillett C. E., Camplejohn R., Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990 Dec;162(4):285–294. doi: 10.1002/path.1711620403. [DOI] [PubMed] [Google Scholar]
  12. Hall P. A., Richards M. A., Gregory W. M., d'Ardenne A. J., Lister T. A., Stansfeld A. G. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 1988 Mar;154(3):223–235. doi: 10.1002/path.1711540305. [DOI] [PubMed] [Google Scholar]
  13. Jain S., Filipe M. I., Hall P. A., Waseem N., Lane D. P., Levison D. A. Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol. 1991 Aug;44(8):655–659. doi: 10.1136/jcp.44.8.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lee S. H., Hurwitz J. Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5672–5676. doi: 10.1073/pnas.87.15.5672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Meyer J. S. Cell kinetic measurements of human tumors. Hum Pathol. 1982 Oct;13(10):874–877. doi: 10.1016/s0046-8177(82)80045-2. [DOI] [PubMed] [Google Scholar]
  16. Ostmeier H., Suter L. The Ki-67 antigen in primary human melanomas--its relationship to mitotic rate and tumor thickness and its stability. Arch Dermatol Res. 1989;281(3):173–177. doi: 10.1007/BF00456388. [DOI] [PubMed] [Google Scholar]
  17. Parums D. V., Cordell J. L., Micklem K., Heryet A. R., Gatter K. C., Mason D. Y. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol. 1990 Sep;43(9):752–757. doi: 10.1136/jcp.43.9.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Porschen R., Lohe B., Hengels K. J., Borchard F. Assessment of cell proliferation in colorectal carcinomas using the monoclonal antibody Ki-67. Correlation with pathohistologic criteria and influence of irradiation. Cancer. 1989 Dec 15;64(12):2501–2505. doi: 10.1002/1097-0142(19891215)64:12<2501::aid-cncr2820641216>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  19. Prioleau P. G., Santa Cruz D. J., Meyer J. S., Bauer W. C. Verrucous carcinoma: a light and electron microscopic, autoradiographic, and immunofluorescence study. Cancer. 1980 Jun 1;45(11):2849–2857. doi: 10.1002/1097-0142(19800601)45:11<2849::aid-cncr2820451122>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  20. Quinn C. M., Wright N. A. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 1990 Feb;160(2):93–102. doi: 10.1002/path.1711600202. [DOI] [PubMed] [Google Scholar]
  21. Rowden G., Fraser R. B. Preparation of "histocomposites" for direct immunohistochemical screening of monoclonal antibodies. Stain Technol. 1988 Jan;63(1):49–52. doi: 10.3109/10520298809107159. [DOI] [PubMed] [Google Scholar]
  22. Sadler D. W., Coghill S. B. Histopathologists, malignancies, and undefined high-power fields. Lancet. 1989 Apr 8;1(8641):785–786. doi: 10.1016/s0140-6736(89)92605-6. [DOI] [PubMed] [Google Scholar]
  23. Silverberg S. G. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. Hum Pathol. 1976 Jul;7(4):451–454. doi: 10.1016/s0046-8177(76)80058-5. [DOI] [PubMed] [Google Scholar]
  24. Strang P., Eklund G., Stendahl U., Frankendal B. S-phase rate as a predictor of early recurrences in carcinoma of the uterine cervix. Anticancer Res. 1987 Jul-Aug;7(4B):807–810. [PubMed] [Google Scholar]
  25. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol. 1989 May;15(1):1–18. doi: 10.1016/0167-8140(89)90113-8. [DOI] [PubMed] [Google Scholar]
  26. Ueda T., Aozasa K., Tsujimoto M., Ohsawa M., Uchida A., Aoki Y., Ono K., Matsumoto K. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer. 1989 Apr 15;63(8):1607–1611. doi: 10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  27. Wan W. H., Fortuna M. B., Furmanski P. A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods. 1987 Oct 23;103(1):121–129. doi: 10.1016/0022-1759(87)90249-3. [DOI] [PubMed] [Google Scholar]
  28. Waseem N. H., Lane D. P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990 May;96(Pt 1):121–129. doi: 10.1242/jcs.96.1.121. [DOI] [PubMed] [Google Scholar]
  29. Weiss L. M., Strickler J. G., Medeiros L. J., Gerdes J., Stein H., Warnke R. A. Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Hum Pathol. 1987 Nov;18(11):1155–1159. doi: 10.1016/s0046-8177(87)80384-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES